Uppsala, Sweden, 2013-09-11 09:30 CEST (GLOBE NEWSWIRE) --
“Ever since Nexttobe became a shareholder of Oasmia, there have been discussions with the largest shareholder Alceco to strengthen the board with one more member. Alexander’s long-time experience from the business community, and especially the life science sector, makes him a valuable addition”, commented Julian Aleksov, CEO of Oasmia.
Prior to joining Nexttobe, Alexander Kotsinas served as Vice President and CFO of Q-Med AB. Previously, he held positions at Life Europe, 3 Scandinavia, Investor and Ericsson. Alexander has a Master of Science from the Royal Institute of Technology in Applied Physics and a Bachelor of Science from Handelshögskolan in Stockholm.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).
Mikael Widell, Vice President Communications, Oasmia Pharmaceutical AB. E-mail: Mikael.widell@oasmia.com Mobile: +46 (0) 703 11 99 60. www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia
